Spiral Therapeutics develops a minimally invasive cochlear drug delivery platform, MICS™, to administer sustained-release steroid formulations directly to the inner ear for the treatment of Ménière’s disease. This approach addresses the lack of FDA-approved therapies for hearing loss by providing targeted, long-lasting drug exposure to manage vertigo and other symptoms effectively.
Funding
$24.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ménière’s disease, a chronic inner ear disorder, lacks FDA-approved drug treatments, leaving patients with debilitating vertigo attacks, tinnitus, fluctuating hearing loss, and aural fullness. Current treatments often fail to provide sustained relief, and drug delivery to the inner ear remains a significant challenge.
Solution
Spiral Therapeutics is developing SPT-2101, a sustained-release steroid formulation delivered via their minimally invasive cochlear system (MICS™) to address inner ear disorders, specifically Ménière’s disease. The MICS™ platform enables precise and durable drug exposure to the cochlea through a clinic-friendly approach. SPT-2101 delivers dexamethasone directly to the round window membrane for extended release, aiming to reduce vertigo and other symptoms. Clinical trial data suggests superior vertigo management compared to controls, with no serious adverse events reported.
Target Audience
The primary target audience includes patients suffering from Ménière’s disease and other inner ear disorders, as well as otolaryngologists and neurotologists seeking effective drug treatments for these conditions.
Features
- Minimally Invasive Cochlear System (MICS™) delivery platform for precise drug placement in the inner ear
- SPT-2101: Sustained-release 6% dexamethasone formulation for extended drug exposure
- Clinic-friendly procedure for direct delivery to the round window membrane
- Demonstrated statistically significant reduction in vertigo compared to control groups in clinical trials (p<0.05)
- No reported serious adverse events or negative impact on hearing in clinical studies
- Potential application for a range of drugs with anti-inflammatory, otoprotective, and neuroprotective activity